semaglutide step versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Semaglutide: The Drug of Today

Analysts now predict that the GLP-1 market could reach $71 billion by 2032, driven by increasing demand for these medications in the treatment of obesity, type 2 diabetes, and cardiovascular conditions

That's why some individuals including many Millennial celebrities in their 30s and 40s are turning to GLP-1s like Ozempic

The post says access decisions center on disease state and risk profile rather than weight status, so a type 2 diabetes diagnosis, cardiovascular risk factors, or metabolic markers can support therapy at a normal BMI

Emily is amazing and very attentive

Insurance Coordinator Our coordination team helps you maximize your insurance coverage for Mounjaro or other GLP-1s